Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease

Trial Profile

Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Antineoplastics; Exemestane; Letrozole; Tamoxifen
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PACS11UNIRAD; UCBG-UNIRAD; UNIRAD
  • Most Recent Events

    • 06 Jun 2023 Results (n=855) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2022 Status changed from active, no longer recruiting to discontinued, according to Results published in the Journal of Clinical Oncology.
    • 23 May 2022 Primary endpoint (To evaluate the benefit from adding everolimus to standard endocrine treatments after two years of treatment on the disease-free survival (DFS)) has not been met, according to Results published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top